Published in Toxins (Basel) on November 15, 2012
Update on staphylococcal superantigen-induced signaling pathways and therapeutic interventions. Toxins (Basel) (2013) 1.03
Differential Role of Rapamycin and Torin/KU63794 in Inflammatory Response of 264.7 RAW Macrophages Stimulated by CA-MRSA. Int J Inflam (2014) 0.75
Arginine Relieves the Inflammatory Response and Enhances the Casein Expression in Bovine Mammary Epithelial Cells Induced by Lipopolysaccharide. Mediators Inflamm (2016) 0.75
TOR signaling in growth and metabolism. Cell (2006) 35.29
AKT/PKB signaling: navigating downstream. Cell (2007) 31.26
Pattern recognition receptors and inflammation. Cell (2010) 21.05
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
The staphylococcal enterotoxins and their relatives. Science (1990) 11.99
Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol (2009) 11.76
NF-kappaB: a key role in inflammatory diseases. J Clin Invest (2001) 9.66
mTOR signaling at a glance. J Cell Sci (2009) 8.66
Interferons, immunity and cancer immunoediting. Nat Rev Immunol (2006) 8.23
Interaction of Staphylococcus aureus toxin "superantigens" with human T cells. Proc Natl Acad Sci U S A (1989) 7.48
T cell activation. Annu Rev Immunol (2009) 7.40
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity (1995) 5.77
The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol (1993) 5.65
The JAK-STAT signaling pathway: input and output integration. J Immunol (2007) 4.92
NF-κB and the link between inflammation and cancer. Immunol Rev (2012) 4.74
Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol (2009) 4.66
The IL-1 family: regulators of immunity. Nat Rev Immunol (2010) 4.65
Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol (2001) 4.48
A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans (2009) 4.37
T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J Exp Med (1992) 4.31
Expanding mTOR signaling. Cell Res (2007) 4.01
T cell stimulation by staphylococcal enterotoxins. Clonally variable response and requirement for major histocompatibility complex class II molecules on accessory or target cells. J Exp Med (1988) 3.90
Superantigens and their potential role in human disease. Adv Immunol (1993) 3.88
Immunopharmacology of rapamycin. Annu Rev Immunol (1996) 3.86
Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol (2002) 3.64
Janus kinases in immune cell signaling. Immunol Rev (2009) 3.60
Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity (2010) 3.27
The chemokine superfamily revisited. Immunity (2012) 2.83
Toxic shock syndrome toxin 1 as an inducer of human tumor necrosis factors and gamma interferon. J Exp Med (1988) 2.61
Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu Rev Immunol (2004) 2.59
Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat Med (2000) 2.55
The bacterial superantigen and superantigen-like proteins. Immunol Rev (2008) 2.44
Bacterial superantigens. Clin Exp Immunol (2003) 2.42
Mutations defining functional regions of the superantigen staphylococcal enterotoxin B. J Exp Med (1992) 2.38
Staphylococcal food poisoning in the United States. New facts and old misconceptions. JAMA (1984) 2.35
HLA-DR alleles differ in their ability to present staphylococcal enterotoxins to T cells. J Exp Med (1990) 2.30
Binding of staphylococcal enterotoxin A to accessory cells is a requirement for its ability to activate human T cells. J Immunol (1988) 2.28
Structural biology of shared cytokine receptors. Annu Rev Immunol (2009) 2.27
Neutrophils cascading their way to inflammation. Trends Immunol (2011) 2.19
Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal (2009) 2.11
Bacterial pyrogenic exotoxins as superantigens. Clin Microbiol Rev (1995) 1.95
Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock. PLoS Biol (2011) 1.93
Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis. Nat Med (2005) 1.88
ENHANCEMENT OF BACTERIAL ENDOTOXIN LETHALITY BY STAPHYLOCOCCAL ENTEROTOXIN. J Infect Dis (1964) 1.87
Binary and ternary complexes between T-cell receptor, class II MHC and superantigen in vitro. Nature (1994) 1.79
AMP-activated protein kinase: new regulation, new roles? Biochem J (2012) 1.75
Clinical manifestations of toxic shock syndrome. JAMA (1981) 1.73
Toxicity of staphylococcal enterotoxins potentiated by lipopolysaccharide: major histocompatibility complex class II molecule dependency and cytokine release. Infect Immun (1993) 1.69
T cell antigen-receptor signal transduction. Curr Opin Immunol (1999) 1.68
Three-dimensional structure of the complex between a T cell receptor beta chain and the superantigen staphylococcal enterotoxin B. Immunity (1998) 1.68
Staphylococcal enterotoxin A has two cooperative binding sites on major histocompatibility complex class II. J Exp Med (1995) 1.58
The kinase PDK1 integrates T cell antigen receptor and CD28 coreceptor signaling to induce NF-kappaB and activate T cells. Nat Immunol (2009) 1.55
Staphylococcal exotoxin activation of T cells. Role of exotoxin-MHC class II binding affinity and class II isotype. J Immunol (1991) 1.50
Transcriptional activation of IL-1 beta and tumor necrosis factor-alpha genes by MHC class II ligands. J Immunol (1991) 1.49
Immune synapses in T-cell activation. Curr Opin Immunol (2006) 1.48
Interleukin 10 protects mice against staphylococcal enterotoxin B-induced lethal shock. Infect Immun (1993) 1.42
Different staphylococcal enterotoxins bind preferentially to distinct major histocompatibility complex class II isotypes. Eur J Immunol (1989) 1.39
Systemic release and protective role of IL-10 in staphylococcal enterotoxin B-induced shock in mice. J Immunol (1994) 1.37
CD28 and T cell antigen receptor signal transduction coordinately regulate interleukin 2 gene expression in response to superantigen stimulation. J Exp Med (1992) 1.36
Superantigen and endotoxin synergize in the induction of lethal shock. Eur J Immunol (1997) 1.31
Microbial superantigens: from structure to function. Trends Microbiol (2000) 1.31
Superantigen mediated shock: a cytokine release syndrome. Immunobiology (1993) 1.29
Bacterial superantigens bypass Lck-dependent T cell receptor signaling by activating a Galpha11-dependent, PLC-beta-mediated pathway. Immunity (2006) 1.26
Subsets of HLA-DR1 molecules defined by SEB and TSST-1 binding. Science (1994) 1.24
Inhibition of bacterial superantigens by peptides and antibodies. Infect Immun (2001) 1.24
Staphylococcus aureus carriers neutralize superantigens by antibodies specific for their colonizing strain: a potential explanation for their improved prognosis in severe sepsis. J Infect Dis (2006) 1.21
Staphylococcal toxins bind to different sites on HLA-DR. J Immunol (1991) 1.21
The mechanism of superantigen-mediated toxic shock: not a simple Th1 cytokine storm. J Immunol (2005) 1.20
Central role for interleukin-2 in type 1 diabetes. Diabetes (2012) 1.19
Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin Infect Dis (2004) 1.18
T-cell signaling: the importance of receptor clustering. Curr Biol (1997) 1.17
Generation, characterization, and epitope mapping of neutralizing and protective monoclonal antibodies against staphylococcal enterotoxin B-induced lethal shock. J Biol Chem (2011) 1.17
Toxic shock syndrome toxin-1 induces inositol phospholipid turnover, protein kinase C translocation, and calcium mobilization in human T cells. J Immunol (1988) 1.17
Superantigen vaccines: a comparative study of genetically attenuated receptor-binding mutants of staphylococcal enterotoxin A. J Infect Dis (1996) 1.12
Immune-mediated side-effects of cytokines in humans. Toxicology (1995) 1.11
Induction of tumor necrosis factor and interleukin-1 by purified staphylococcal toxic shock syndrome toxin 1 requires the presence of both monocytes and T lymphocytes. Infect Immun (1992) 1.11
Role of protein tyrosine phosphorylation in monokine induction by the staphylococcal superantigen toxic shock syndrome toxin-1. J Immunol (1992) 1.11
In vitro and in vivo evaluation of staphylococcal superantigen peptide antagonists. Infect Immun (2004) 1.11
Lethal synergism between influenza infection and staphylococcal enterotoxin B in mice. J Immunol (1996) 1.09
Superantigen shock in mice with an inapparent viral infection. J Infect Dis (1994) 1.08
Induction of acute inflammation in vivo by staphylococcal superantigens. II. Critical role for chemokines, ICAM-1, and TNF-alpha. J Immunol (1998) 1.07
Induction of acute inflammatory lung injury by staphylococcal enterotoxin B. J Immunol (1997) 1.07
Cross-linking of MHC class II molecules by staphylococcal enterotoxin A is essential for antigen-presenting cell and T cell activation. J Immunol (1996) 1.05
Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines. Antimicrob Agents Chemother (2003) 1.05
Cross-reactive antibodies prevent the lethal effects of Staphylococcus aureus superantigens. J Infect Dis (1999) 1.05
Anti-gamma interferon and anti-interleukin-6 antibodies affect staphylococcal enterotoxin B-induced weight loss, hypoglycemia, and cytokine release in D-galactosamine-sensitized and unsensitized mice. Infect Immun (1995) 1.04
Superantigen can reactivate bacterial cell wall-induced arthritis. J Immunol (1993) 1.04
Structural basis of T-cell specificity and activation by the bacterial superantigen TSST-1. EMBO J (2007) 1.03
Inhibition of toxic shock by human monoclonal antibodies against staphylococcal enterotoxin B. PLoS One (2010) 1.03
Suppression of acute lung inflammation by intracellular peptide delivery of a nuclear import inhibitor. Mol Ther (2009) 1.03
Multiple anti-inflammatory pathways triggered by resveratrol lead to amelioration of staphylococcal enterotoxin B-induced lung injury. Br J Pharmacol (2012) 1.01
Analysis of superantigenic toxin Vbeta T-cell signatures produced during cases of staphylococcal toxic shock syndrome and septic shock. Clin Microbiol Infect (2008) 1.01
Induction of CC chemokines in human peripheral blood mononuclear cells by staphylococcal exotoxins and its prevention by pentoxifylline. J Leukoc Biol (1999) 1.00
Staphylococcal toxic shock syndrome toxin 1-induced tumor necrosis factor alpha and interleukin-1 beta secretion by human peripheral blood monocytes and T lymphocytes is differentially suppressed by protein kinase inhibitors. Infect Immun (1992) 1.00
Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig. J Immunol (1996) 0.99
Potent neutralization of staphylococcal enterotoxin B by synergistic action of chimeric antibodies. Infect Immun (2010) 0.99
Evidence for the involvement of bacterial superantigens in psoriasis, atopic dermatitis, and Kawasaki syndrome. FEMS Microbiol Lett (2000) 0.98
Tumor necrosis factor and anti-tumor necrosis factor therapies. J Rheumatol Suppl (2010) 0.98
Steroid therapy of septic shock. Crit Care Clin (2009) 0.98
Superantigen recognition by HLA class II on monocytes up-regulates toll-like receptor 4 and enhances proinflammatory responses to endotoxin. Blood (2005) 0.97